These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Differentiation between basal cell carcinoma and trichoepithelioma by immunohistochemical staining of the androgen receptor: an overview. Arits AH; Van Marion AM; Lohman BG; Thissen MR; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW Eur J Dermatol; 2011; 21(6):870-3. PubMed ID: 21865121 [TBL] [Abstract][Full Text] [Related]
9. The management of solitary trichoepithelioma versus basal cell carcinoma. Votruba M; Collins CM; Harrad RA Eye (Lond); 1998; 12 ( Pt 1)():43-6. PubMed ID: 9614515 [TBL] [Abstract][Full Text] [Related]
10. Trichoepithelioma with an adjacent basal cell carcinoma, transformation or collision? Wallace ML; Smoller BR J Am Acad Dermatol; 1997 Aug; 37(2 Pt 2):343-5. PubMed ID: 9270544 [TBL] [Abstract][Full Text] [Related]
11. Differentiation of Basal Cell Carcinoma and Trichoepithelioma: An Immunohistochemical Study. Carrasquillo OY; Cruzval-O'Reilly E; Sánchez JE; Valentín-Nogueras SM Am J Dermatopathol; 2021 Mar; 43(3):191-197. PubMed ID: 32809979 [TBL] [Abstract][Full Text] [Related]
12. The use of immunostaining for bcl-2 and CD34 and the lectin peanut agglutinin in differentiating between basal cell carcinomas and trichoepitheliomas. Basarab T; Orchard G; Russell-Jones R Am J Dermatopathol; 1998 Oct; 20(5):448-52. PubMed ID: 9790103 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of the mechanistic target of rapamycin and hypoxia signalling pathways in basal cell carcinoma and trichoepithelioma. Brinkhuizen T; Weijzen CA; Eben J; Thissen MR; van Marion AM; Lohman BG; Winnepenninckx VJ; Nelemans PJ; van Steensel MA PLoS One; 2014; 9(9):e106427. PubMed ID: 25181405 [TBL] [Abstract][Full Text] [Related]
14. Papillary mesenchymal bodies: a histologic finding useful in differentiating trichoepitheliomas from basal cell carcinomas. Brooke JD; Fitzpatrick JE; Golitz LE J Am Acad Dermatol; 1989 Sep; 21(3 Pt 1):523-8. PubMed ID: 2778115 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of immunohistochemical markers in differentiation between basal cell carcinoma and trichoepithelioma in small biopsy specimens. Mostafa NA; Assaf M; Elhakim S; Abdel-Halim MRE; El-Nabarawy E; Gharib K J Cutan Pathol; 2018 Nov; 45(11):807-816. PubMed ID: 29917261 [TBL] [Abstract][Full Text] [Related]
17. [Desmoplastic trichoepithelioma: a clinicopathological study, including a comparison with morpheiform basal cell carcinoma]. Mitcov M; Scrivener Y; Cribier B Ann Dermatol Venereol; 2009; 136(6-7):501-7. PubMed ID: 19560610 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of CD34 immunostaining in desmoplastic trichilemmoma. Illueca C; Monteagudo C; Revert A; Llombart-Bosch A J Cutan Pathol; 1998 Sep; 25(8):435-9. PubMed ID: 9826169 [TBL] [Abstract][Full Text] [Related]
19. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293 [TBL] [Abstract][Full Text] [Related]
20. Panel vs. single marker for discriminating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma. Vollmer RT J Cutan Pathol; 2009 Feb; 36(2):283; author reply 284. PubMed ID: 19208081 [No Abstract] [Full Text] [Related] [Next] [New Search]